CERO Therapeutics Holdings, Inc. announced on June 2, 2025, a significant expansion of its intellectual property portfolio with the granting of two U.S. patents and the allowance of one European patent application. U.S. Patent No. 12,291,557, covering design aspects of CER-1236, was granted on May 6, 2025, providing composition of matter protection for a chimeric TIM4 receptor.
Additionally, U.S. Patent No. 12,303,551, covering combination cellular immunotherapy compositions and methods of use for CER-1236, was granted on May 20, 2025. This patent protects the combination of a chimeric engulfment receptor CD4+ T cell with a chimeric antigen receptor CD8+ T cell or T cell receptor CD8+ T cell for cancer treatment. The European Patent Office also allowed European Patent Application No. 1882166.7 on May 16, 2025, expanding protection for additional design aspects of CER-1236.
These additions bring CERO’s total to 18 issued patents and allowed patent applications internationally across nine patent families, with U.S. protection extending out to 2042. CEO Chris Ehrlich emphasized that this aggressive expansion ensures CERO’s market success by protecting the core innovations that differentiate its CER-T technology from other cell therapies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.